Evidence map›Paper›PMID 33376721›Full record

ReviewBioMed research international2020

Natural Products: Review for Their Effects of Anti-HBV.

Xuqiang Liu, Changyang Ma, Zhenhua Liu, Wenyi Kang

Abstract readReview
In one paragraph

Review in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. The progress of molecules and strategies for the treatment of HBV infection.Frontiers in cellular and infection microbiology · 2023
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xuqiang LiuNational R & D Center for Edible Fungus Processing Technology, Henan University, Kaifeng 475004, China.ORCID https://orcid.org/0000-0002-9345-5631
Changyang MaNational R & D Center for Edible Fungus Processing Technology, Henan University, Kaifeng 475004, China.ORCID https://orcid.org/0000-0003-1583-9741
Zhenhua LiuNational R & D Center for Edible Fungus Processing Technology, Henan University, Kaifeng 475004, China.ORCID https://orcid.org/0000-0002-0053-1923
Wenyi KangNational R & D Center for Edible Fungus Processing Technology, Henan University, Kaifeng 475004, China.ORCID https://orcid.org/0000-0002-1822-6249

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis B is a global infectious disease, seriously endangering human health. Currently, there are mainly interferons and nucleoside analogues treatment of hepatitis B in the clinic, which have certain therapeutic effects on hepatitis B, but their side effects and drug resistance are increasingly prominent. Therefore, it is urgently needed to discover and develop new anti-HBV drugs, especially natural products, which have novel, high efficiency, and low toxicity anti-HBV compounds with novel antiviral mechanisms. In this manuscript, the natural products (polysaccharides and 165 compounds) with the activity of antihepatitis B virus are discussed according to their chemical classes, including 14 phenylpropanoids, 8 flavonoids,12 xanthones, 13 anthroquinones, 47 terpenoids, 6 alkaloids, 15 enediynes, 11 aromatics, 18 phenylalanine dipeptides compounds, and 13 others. In addition, the anti-HBV mechanism and targets of natural product were also discussed. The aim of this review is to report new discoveries about anti-HBV natural products and to provide reference for researchers.

Indexed as

AlkaloidsAntiviral AgentsBiological ProductsDipeptidesEnediynesFlavonoidsHepatitis B, ChronicHepatitis B virusHumansInhibitory Concentration 50LactonesPhenylalaninePolysaccharidesTerpenesXanthonesAlkaloidsAntiviral AgentsBiological ProductsDipeptidesEnediynesFlavonoidsLactonesPhenylalaninePolysaccharidesTerpenesXanthones

Identifiers

PMID33376721
PMCPMC7746453

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.